Dose density is a way of scheduling cancer drug treatment so doses are given closer together in time. It is most often discussed in chemotherapy, where the interval between treatment cycles is shortened. The goal is to deliver the planned treatment intensity without lowering the individual drug doses. Dose density is commonly used in selected curative-intent regimens, especially in some solid tumors and lymphomas.
Dose intensity is a way clinicians describe how much anti-cancer drug is delivered over a set period of time. It combines the drug dose and the treatment schedule into a single concept. It is most commonly discussed in chemotherapy and other systemic cancer therapies. It is also used in clinical trials and treatment planning to compare regimens.
A Treatment holiday is a planned, temporary pause in cancer treatment. It is most commonly discussed in medical oncology for systemic therapies, such as chemotherapy, targeted therapy, immunotherapy, or endocrine therapy. The goal is usually to balance cancer control with side effects, quality of life, or recovery needs. It is different from stopping treatment permanently, and it is typically paired with monitoring and a plan for reassessment.
Previously treated means a person has already received one or more therapies for a cancer or related condition. It is a clinical label used in oncology notes, pathology reports, treatment plans, and clinical trials. It helps describe where someone is in their cancer-care journey and what options may be considered next. The exact meaning depends on the cancer type, stage, and which treatments were given.
Treatment-naïve means a person has not yet received a specific cancer treatment. It is commonly used in oncology clinics and clinical trials to describe baseline status before therapy starts. The term can apply to all cancer treatments or to a particular type, such as immunotherapy-naïve or chemotherapy-naïve. It helps clinicians and researchers interpret test results and compare outcomes more fairly.
Third-line therapy is cancer treatment given after two previous treatments (first-line and second-line) have not controlled the cancer or were not tolerated. It is commonly used in advanced or recurrent cancers, where the disease has returned or continued to grow. Third-line therapy may aim to slow cancer growth, reduce symptoms, or improve quality of life. The exact treatment can differ widely depending on the cancer type and the person’s overall health.
Second-line therapy is cancer treatment given after an earlier treatment has not worked well enough or can no longer be continued. It is most often used when cancer grows during treatment, returns after treatment, or side effects make the first plan unsafe to continue. Second-line therapy can be medicine, radiation, surgery, a procedure, or supportive care, depending on the cancer. It is commonly discussed in medical oncology and hematology-oncology, and it may also involve radiation and surgical teams.
First-line therapy is the initial treatment chosen for a specific cancer in a specific clinical situation. It is typically the option with the strongest evidence of benefit for that setting. It is commonly discussed when a cancer is newly diagnosed, has returned, or has spread. It can include surgery, radiation, systemic drugs, or a combination, depending on the case.
Line of therapy is a clinical term for the sequence of cancer treatments a person receives over time. It labels each planned “round” of treatment, such as first-line treatment and second-line treatment. It is commonly used in oncology visits, tumor boards, clinical notes, and clinical trials. It helps teams communicate what has been tried, what worked, and what may come next.
Salvage therapy is treatment given after a cancer has not responded to the first planned treatment or has come back after an initial response. It is a broad term that can include surgery, radiation therapy, systemic drug therapy, or combinations of these. In oncology, it is commonly used in both solid tumors and blood cancers when the goal is to regain disease control. The exact approach depends on the cancer type, prior treatments, and where the cancer is located now.